The global viral vector and plasmid DNA manufacturing market is growing on rising demand for gene therapy, precision medicine, and regenerative medicine. Valued at USD 6.46 billion in 2025, the market is projected to reach USD 7.36 billion in 2026 and USD 21.28 billion by 2034, growing at a CAGR of 14.16% during the forecast period 2026–2034. Europe held the largest regional share in 2025 at 42.0%. Key players include Thermo Fisher Scientific Inc., Lonza Group, Merck KGaA, Catalent Inc., Sartorius AG, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Oxford Biomedica, AGC Biologics, Kaneka Corporation, VGXI Inc., and WuXi Advanced Therapies.

How the Viral Vector and Plasmid DNA Manufacturing Market Works

Viral vector and plasmid DNA manufacturing refers to the production of biological products used in gene therapy, cell therapy, and vaccines, which deliver genetic material into target cells. The supply chain spans raw material suppliers, producers, contract development and manufacturing organizations, testing service providers, distributors, and end users. Production consists of upstream manufacturing, purification, quality testing, and fill-finish, with final products delivered to pharmaceutical and biotechnology firms.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/viral-vector-and-plasmid-dna-manufacturing-market

AAV Vectors Lead the Product Segment

AAV vectors accounted for the largest product share, 31.0%, in 2025, owing to wide use in commercial gene therapy manufacturing and benefiting from regulatory approvals and clinical adoption. In June 2026, SK pharmteco launched the SKyvec high-yield viral vector platform to improve scalable AAV and lentiviral manufacturing. In May 2026, Cell and Gene Therapy Catapult invested in Lir Therapeutics, which is developing an AI-driven AAV capsid design platform.

Lentiviral vectors are the fastest-growing product segment, with a projected CAGR of 14.4%, driven by use in CAR-T cell therapy and stem cell research. Growing clinical development activity supports demand, and Oxford Biomedica is positioned as a niche leader in lentiviral platforms. Polaris notes that lentiviral vectors and AAV carry high manufacturing complexity.

Upstream Processing and Downstream Purification

Upstream processing dominated the workflow category with a 42.0% share in 2025 due to increasing commercial production of viral vectors and plasmid DNA, as companies invest in advanced bioreactor technologies to improve production efficiency. Downstream purification is projected to grow fastest, at a CAGR of 15.0%, because rising demand for high-purity biological products is increasing investment in purification technologies.

Automation and process digitalization are supporting quality across both stages. Polaris classifies automation as a growing deployment that improves manufacturing efficiency, digital analytics as early commercial, and quality management systems as mainstream. Growth in commercial manufacturing platforms is expected to drive large-scale production, and Polaris classifies commercial-scale manufacturing as early commercial, with capacity expansion improving product availability.

Single-Use Bioprocessing Systems and Cost Efficiency

Firms are using automated systems, single-use bioprocessing systems, and sophisticated purification methods to improve scalability and reduce time and cost. Polaris describes single-use manufacturing as a growing deployment of flexible production platforms that reduce production time. Single-use bioprocessing systems help address the market's main restraint: high manufacturing costs linked to special facilities, skilled professionals, and stringent quality control. In January 2025, Asimov and AGC Biologics partnered on a single-plasmid production platform to streamline and reduce the cost of viral vector manufacturing.

Regional Outlook

Europe's 42.0% share rests on favorable regulations and established biopharmaceutical facilities, with Germany, the UK, Switzerland, and France as key hubs. In March 2026, New England Biolabs and Touchlight introduced the EnClose Cell-free dbDNA Synthesis Kit, offering a scalable route that speeds viral vector and plasmid DNA manufacturing compared with traditional plasmid production. North America held 24.0% in 2025. Asia Pacific is projected to grow fastest, at a CAGR of 16.7%, as China, Japan, South Korea, India, and Singapore expand capacity for advanced biologics. Barriers to entry include high capital investment, strict regulatory requirements, and complex validation. Even so, upstream processing efficiency, downstream purification capability, and demand for AAV vectors point to steady expansion through 2034.

More Trending Latest Reports By Polaris Market Research:

Military Simulation And Virtual Training Market

Microencapsulated Pesticides Market

Acrylic Resins Market

GPU Server Market

Earth Observation Small Satellite Market

Extreme Ultraviolet Lithography Market

Viral Vector And Plasmid DNA Manufacturing Market

Distributed Energy Resource Management System Market